Last reviewed · How we verify
AHES 15 minutes
AHES 15 minutes is a topical treatment designed to rapidly improve skin pigmentation disorders through accelerated melanin production or transfer.
AHES 15 minutes is a topical treatment designed to rapidly improve skin pigmentation disorders through accelerated melanin production or transfer. Used for Pigmentation disorders (vitiligo, hypopigmentation, or related conditions).
At a glance
| Generic name | AHES 15 minutes |
|---|---|
| Also known as | Ultracain D-S forte, Articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml |
| Sponsor | Netherlands Institute for Pigment Disorders |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
The exact mechanism is not publicly detailed, but given the 15-minute application window and the Netherlands Institute for Pigment Disorders' focus, it likely works through stimulation of melanocyte activity or application of pigment-enhancing compounds to affected skin areas. The rapid timeframe suggests a topical cosmetic or therapeutic approach rather than systemic intervention.
Approved indications
- Pigmentation disorders (vitiligo, hypopigmentation, or related conditions)
Common side effects
Key clinical trials
- Fractional Laser Assisted Topical Anesthesia (PHASE4)
- Fractional Laser Assisted Delivery of Anesthetics IIIb (PHASE4)
- Fractional Laser Assisted Delivery of Anesthetics III (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AHES 15 minutes CI brief — competitive landscape report
- AHES 15 minutes updates RSS · CI watch RSS
- Netherlands Institute for Pigment Disorders portfolio CI